Engineered microparticles and nanoparticles for fibrinolysis.

Area of Science:

• Biomedical Engineering
• Thrombosis Research
• Nanomedicine

Background:

• Fibrinolytic agents like plasmin improve outcomes in ischemic stroke and thrombosis by dissolving clots.
• Current fibrinolytic therapies have limitations including short circulation times, degradation, and bleeding risks.
• Engineered nanoparticles offer potential solutions to enhance fibrinolytic agent delivery and efficacy.

Purpose of the Study:

• To review recent advances in coupling fibrinolytic agents with engineered particles.
• To highlight strategies for improving circulation, targeting, and reducing side effects of fibrinolytic therapies.
• To discuss challenges in translating these particle-based approaches to clinical practice.

Main Methods:

• Modification of plasminogen activators with macromolecules.
• Encapsulation of fibrinolytic agents (plasminogen activators, plasmin) in polymer and liposomal particles.
• Integration of triggered release mechanisms (e.g., ultrasound) and targeted delivery systems (e.g., magnetic particles).

Main Results:

• Particle-based approaches demonstrate improved circulation time, enhanced clot recanalization, and reduced off-target effects in preclinical studies.
• Macromolecular modifications and encapsulation protect fibrinolytic agents from degradation.
• Targeted delivery systems show potential for precise clot dissolution with minimized systemic exposure.

Conclusions:

• Engineered nanoparticles and microparticles represent a promising strategy to overcome limitations of conventional fibrinolytic agents.
• Further research and development are needed to address technical challenges for clinical translation.
• These advanced therapies hold potential for improved treatment of acute ischemic stroke and thrombosis.